Cyclin-dependent Kinase 5 Promotes Myc Stabilization Through Inhibitory Phosphorylation of GSK-3β in Ewing Sarcoma

Masanori Kawano1, Yuta Kubota2, Ichiro Itonaga2

  • 1Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Yufu, Japan; kawano@oita-u.ac.jp.

Anticancer Research
|March 27, 2026
PubMed
Abstract

Insights

Cyclin-dependent kinase 5 (CDK5) suppresses tumor suppressor Glycogen synthase kinase-3β (GSK-3β) activity in Ewing sarcoma. This leads to Myc protein accumulation and increased cell proliferation, suggesting CDK5 as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Glycogen synthase kinase-3β (GSK-3β) acts as a tumor suppressor by promoting Myc protein ubiquitination and degradation.
  • Understanding the regulation of GSK-3β activity is crucial for cancer research.

Purpose of the Study:

  • To investigate the role of cyclin-dependent kinase 5 (CDK5) in regulating GSK-3β activity.
  • To examine the impact of CDK5 on Myc phosphorylation and ubiquitination in Ewing sarcoma cells.

Main Methods:

  • Ewing sarcoma cell lines were utilized.
  • Cells were transfected with CDK5 or GSK-3β expression vectors, or treated with siRNA.
  • Analysis included cell proliferation, cell-cycle progression, apoptosis, protein phosphorylation, and ubiquitination assays.

Main Results:

  • CDK5 overexpression increased Ewing sarcoma cell proliferation and cell-cycle progression.
  • CDK5 induced inhibitory phosphorylation of GSK-3β, leading to its inactivation.
  • This resulted in decreased Myc ubiquitination and accumulation of Myc protein.

Conclusions:

  • CDK5 functionally impairs GSK-3β, leading to Myc upregulation and promoting Ewing sarcoma cell proliferation.
  • The CDK5-mediated regulation of GSK-3β and Myc represents a potential therapeutic strategy for Ewing sarcoma.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

3.0K